Holen Sie sich die Stockscreener-App
1.75
19.35%
-0.42
Schlusskurs vom Vortag:
$2.17
Offen:
$1.85
24-Stunden-Volumen:
2.08M
Relative Volume:
9.04
Marktkapitalisierung:
$70.97M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-13.27M
KGV:
-10.67
EPS:
-0.164
Netto-Cashflow:
$-7.70M
1W Leistung:
-8.85%
1M Leistung:
-43.73%
6M Leistung:
-34.46%
1J Leistung:
+64.32%
1-Tages-Spanne:
$1.55
$1.85
1-Wochen-Bereich:
$1.55
$2.28
52-Wochen-Spanne:
$1.03
$3.349
Okyo Pharma Limited Stock (OKYO) Company Profile
Firmenname
Okyo Pharma Limited
Sektor
Branche
Telefon
-
Adresse
-
Compare OKYO vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OKYO
Okyo Pharma Limited
|
1.75 | 88.00M | 0 | -13.27M | -7.70M | -0.164 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Okyo Pharma Limited Stock (OKYO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-08 | Eingeleitet | B. Riley Securities | Buy |
Okyo Pharma Limited Aktie (OKYO) Neueste Nachrichten
OKYO Pharma prices public offering at $1.85/share to raise up to $20M - MSN
Published on: 2026-02-14 12:01:38 - baoquankhu1.vn
Small cap wrap: OKYO Pharma, HIVE Digital Technologies, Synchronoss Technologies... - Proactive financial news
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Sees Significant Increase in Short Interest - MarketBeat
What risks investors should watch in OKYO Pharma Limited stockJuly 2025 PreEarnings & Weekly Chart Analysis and Trade Guides - mfd.ru
OKYO Pharma announces $20 million public offering of ordinary shares By Investing.com - Investing.com Canada
OKYO Pharma Prices $20 Million Underwritten Share Offering to Fund Clinical Development - TipRanks
OKYO Pharma stock tumbles on $20 million public offering announcement - Investing.com
OKYO Pharma prices $20M offering to fund late-stage eye drug trial - Proactive financial news
OKYO Pharma Prices $20 Million Public Share Offering to Fund Eye Disease Pipeline - TipRanks
OKYO Pharma announces $20 million public offering of ordinary shares - Investing.com
What’s the analyst consensus on OKYO Pharma LimitedOptions Play & Technical Entry and Exit Tips - mfd.ru
OKYO Pharma Limited Prices Public Offering of Ordinary Shares to Raise Approximately $20 Million - Quiver Quantitative
OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares - The Manila Times
Okyo Pharma Ltd Announces Pricing Of $20 Million Public Offering Of Ordinary Shares - TradingView
OKYO Pharma Prices Public Offering at $1.85 per Share - Intellectia AI
Okyo Pharma announces ordinary shares offering, no amount given - TipRanks
OKYO Pharma launches underwritten public offering of ordinary shares - MSN
OKYO Pharma Launches Public Offering to Fund Next Phase of Corneal Pain Drug Development - TipRanks
OKYO Pharma Announces Public Offering of Ordinary Shares - Bitget
OKYO Pharma Announces Public Offering of Ordinary Shares - Benzinga
OKYO Pharma Appoints Flavio Mantelli, MD, as Chief Medical Officer - VisionMonday.com
Is OKYO Pharma Limited a potential multi bagger2025 Valuation Update & Weekly Sector Rotation Insights - mfd.ru
Volatility Watch: Will JBG SMITH Properties outperform tech stocksJuly 2025 Trade Ideas & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Small cap wrap: OKYO Pharma, Arizona Gold & Silver, Standard Uranium, C3 Metals… - Proactive financial news
OKYO Pharma transitions ATM equity offering to Leerink Partners as sales agent - Investing.com Nigeria
OKYO Pharma appoints Leerink Partners as sales agent for ATM equity offering - Proactive financial news
OKYO Pharma Switches ATM Equity Facility to Leerink Partners to Support Urcosimod Push - TipRanks
OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners - The Manila Times
OKYO Pharma Limited Transitions ATM Equity Offering to Leerink Partners LLC for Enhanced Capital Access - Quiver Quantitative
OKYO Pharma taps Leerink to raise cash for eye pain treatments - Stock Titan
Is OKYO Pharma Limited a turnaround storyJuly 2025 Snapshot & Low Drawdown Trading Techniques - mfd.ru
How interest rate cuts could boost OKYO Pharma Limited stockCEO Change & Safe Investment Capital Preservation Plans - mfd.ru
OKYO Pharma Launches $50 Million At-the-Market Share Offering With Leerink Partners - TipRanks
OKYO Pharma appoints former Dompé CMO Flavio Mantelli to lead NCP program - Investing.com Australia
OKYO Pharma appoints former Dompé CMO Flavio Mantelli to lead NCP program By Investing.com - Investing.com South Africa
OKYO Pharma appoints Flavio Mantelli as chief medical officer - Proactive financial news
OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer - BioSpace
OKYO Pharma Hires Oxervate Veteran Flavio Mantelli as Chief Medical Officer to Drive Urcosimod Program - TipRanks
Doctor behind $1B rare-disease eye drug joins OKYO Pharma - Stock Titan
What are OKYO Pharma Limited’s growth leversJuly 2025 Analyst Calls & Consistent Profit Trade Alerts - mfd.ru
Published on: 2026-02-04 02:26:16 - baoquankhu1.vn
OKYO Pharma’s neuropathic corneal pain study greenlit by FDAICYMI - Proactive financial news
OKYO Pharma to present urcosimod Phase 2 results at ASCRS 2026 annual meeting - Proactive financial news
OKYO Pharma to present urcosimod NCP study results at ASCRS meeting - Investing.com Nigeria
OKYO Pharma Advances Urcosimod With Positive Interim Results and FDA Alignment on Phase 2b/3 NCP Trial - TipRanks
Small cap wrap: OKYO Pharma, NEXE Innovations, Delivra Health Brands… - Proactive Investors
OKYO Pharma to present urcosimod NCP study results at ASCRS meeting By Investing.com - Investing.com South Africa
OKYO Pharma’s Urcosimod Phase 2 Data Accepted for Presentation at 2026 ASCRS Meeting - TipRanks
Finanzdaten der Okyo Pharma Limited-Aktie (OKYO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):